Close Menu

OHSU

With the participation of five cancer centers and clinics, Taproot is hoping to build a national, prospective data registry that is much needed but has been difficult to advance to date.

Within the master observational trial, the organizations have agreed to prospectively collect real world data and ultimately build a national oncology database.

Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.